SMi presents the 9th Annual Conference on Biosimilars & Biobetters
Forecasting the next wave of biosimilars to ensure optimal market commercialisation
The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.
We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?
Join us to hear experiences of key opinion leaders and evaluate market access, opportunities and commercialisation strategies with industry-thought experts.
This event is CPD accredited.
#SMiBiosimilars
WHO SHOULD ATTEND
Chief Executives, Vice Presidents, Executive Directors, Directors, Heads, Managers and Specialists from the following, but not limited to, sectors should attend:
- Biosimilars / Biologics
- Biopharmaceuticals
- Research and Development
- Legal Affairs
- Intellectual Property
- Regulatory Compliance
- Quality affairs and control
- Pharmacovigilance, Drug Safety and Risk Management
- Business Development
- Commercialisation
- Marketing and sales
EARLY BIRD-RATES
- BOOK BY 30TH APRIL AND SAVE £400
- BOOK BY 31ST MAY AND SAVE £200
- BOOK BY 29TH JUNE AND SAVE £100
To learn more about this event, and to register online, visit http://www.biosimilars-europe.com/pharmajournalistWL